|
|
Tune in this Sunday, Dec. 17, at 5:30 p.m. ET on the Fox Business Network to learn about Gb Sciences cannabinoidbased medicine for the treatment of Parkinsons disease.LAS VEGAS, NV / ACCESSWIRE / December 14, 2023 /... Lire le communiqué |
|
| |
|
| |
|
|
The Parkinsons disease market is expected to grow to $12.8 billion by 2028.LAS VEGAS, NV / ACCESSWIRE / July 11, 2023 / Gb Sciences, Inc. OTCQB:GBLX, a leading cannabis and plantinspired biopharmaceutical research and development company, has successfully completed a dose response study in rodents at the University of Lethbridge that supports Gb Sciences cannabinoidbased therapy for Parkinsons... Lire le communiqué |
|
| |
|
| |
|
|
According to Statista, China has the second largest pharmaceutical market in the world and plantbased medicines are very well accepted, which makes China a potential target market for Gb Sciences.LAS VEGAS, NV / ACCESSWIRE / March 20, 2023 / Gb Sciences, Inc. OTCQB:GBLX, a leading cannabis and plantinspired biopharmaceutical research and development company, has recently been issued a patent... Lire le communiqué |
|
| |
|
| |
|
|
Biopharmaceutical research company specializing in cannabis and plantinspired medicines shares strategic plan for 2023 and key developments from 2022LAS VEGAS, NV / ACCESSWIRE / March 7, 2023 / Gb Sciences, Inc. OTCQB:GBLX, a leading cannabis and plantinspired biopharmaceutical research and development company, issued a letter to shareholders today from President, Chief Science Officer, and... Lire le communiqué |
|
| |
|
| |
